ALK and lung cancer: To provide a more clinically relevant assessment, we utilized the dataset from Maynard et al. [37], which includes single-cell RNA-seq data from clinical biopsies of lung cancer patients, encompassing both treatment-naïve (TN) and progressive disease (PD) cases, including several ALK + samples.